ライフサイエンスコーパス: mania

1 a novel approach to the treatment of bipolar mania.

2 tivity or energy" as a primary criterion for mania.

3 and motivation in children at high risk for mania.

4 ion of behavioral features characteristic of mania.

5 t adolescence as the peak period of onset of mania.

6 ractive reward processing network, underlies mania.

7 he behavioral manifestations seen in bipolar mania.

8 ractivity, a frequently used animal model of mania.

9 of illness and to identify any hypomania or mania.

10 and least pervasive in bipolar disorder and mania.

11 the criterion standard for animal models of mania.

12 s known to cause switches from depression to mania.

13 to examine correlates of treatment-emergent mania.

14 recovered from mania, but 73.3% relapsed to mania.

15 et of treatment and a measure of response in mania.

16 ildhood IQ predicted increased risk of adult mania.

17 a GSK-3beta inhibitor in this mouse model of mania.

18 ar depression without increasing the risk of mania.

19 (2) Medical conditions that mimic mania.

20 optimal blood levels for treatment of acute mania.

21 ed at the most severe levels of hypomania or mania.

22 ng-episode duration, and chronicity of child mania.

23 ed to treatment and the rate of switching to mania.

24 xed), and 38.7% +/- 28.8% of these were with mania.

25 achieving remission from an episode of acute mania.

26 indings from a first such study of late-life mania.

27 erity who are likely to be treated for acute mania.

28 were more frequently studied than for acute mania.

29 ure, as well as efficacy in a mouse model of mania.

30 depression may reflect differential risk of mania.

31 cantly higher risk of incident and recurrent mania.

32 r characterized by periods of depression and mania.

33 ted the effects of recent stressors on adult mania.

34 tient treatment, such as active psychosis or mania.

35 chronic recurrent episodes of depression and mania.

36 apy was associated with an increased risk of mania.

37 nts during bipolar mixed states or dysphoric manias.

38 individual were used to compare the rate of mania 0-3 months and 3-9 months after the start of antid

39 sedation (7.7%) in the open-label period and mania (11.9% of the placebo group compared with 4.0% of

40 for depression, 1.83 (95% CI=1.72-1.94); for mania, 4.35 (95% CI=3.67-5.16); for delirium, confusion,

41 tress responsivity are prominent symptoms of mania, a behavioral state common to schizophrenia and bi

42 group had a better outcome compared with the mania absent and chronic mania groups (12-point and 8-po

43 owed 2 discontinuities demarcating 3 groups: mania absent, episodic mania, and chronic mania (manic/h

44 and/or a history of postpartum psychosis or mania according to DSM or ICD criteria or the Research D

45 D), which is characterized by depression and mania, affects 1-2% of the world population.

46 Psychosis or mania after childbirth is a psychiatric emergency with r

47 l phenotypes reminiscent of aspects of human mania, ameliorated by antimania drugs lithium and valpro

48 tween methylphenidate and treatment-emergent mania among patients with bipolar disorder who were conc

49 -naive adolescents in their first episode of mania and 17 healthy subjects underwent diffusion tensor

50 es of the dimensions and factor structure of mania and bipolar depression and (2) longitudinal studie

51 f isolated behaviors and domains involved in mania and bipolar disorder will ultimately inform moveme

52 ing the dopamine synthesis and/or release in mania and DAT blockade in bipolar depression.

53 cious than placebo in the treatment of acute mania and demonstrated a rapid onset of action.

54 Hazard ratios were similar for mania and depression events (0.30 and 0.33, respectively

55 and is required to mediate endophenotypes of mania and depression in rodents.

56 iscoveries of pharmacological treatments for mania and depression several decades ago, relatively lit

57 hat are often used to manage the episodes of mania and depression that characterize bipolar disorder.

58 Separate inheritance of mania and depression together with high rates of clinica

59 te depressive episodes and in prophylaxis of mania and depression, and lamotrigine in prophylaxis (re

60 t of bipolar disorders to prevent relapse of mania and depression, but many patients do not have a re

61 ten abstracted by separate animal models for mania and depression.

62 sease characterized by recurrent episodes of mania and depression.

63 at is characterized by recurrent episodes of mania and depression.

64 tric illness marked by recurrent episodes of mania and depression.

65 is characterized by intermittent episodes of mania and depression; without treatment, 15% of patients

66 Although mania and hypomania define bipolar disorder, depressive

67 essive disorder; depression more common than mania and hypomania in bipolar disorders; trait mood lab

68 ed as a coprimary symptom, the prevalence of mania and hypomania was reduced.

69 ntified in the DSM-5 as cardinal symptoms of mania and hypomania.

70 t onset as manic, major depressive, or both (mania and major depression in the same onset year).

71 Self-reported ages at onset of mania and major depression were used to code polarity at

72 opposite to the direction seen in bipolar I mania and may therefore be state dependent, the observed

73 ely ill patients with schizophrenia, bipolar mania and MDD compared with controls (P<0.01).

74 re was no evidence for cross-transmission of mania and MDEs (OR=.7, CI:.5-1.1), psychosis and mania (

75 ns of neural activation predict the onset of mania and other mood disorders in high-risk children.

76 careful definition and follow-up of emerging mania and partial remission.

77 FRN as a biological vulnerability marker for mania and pathological risk-taking.

78 ar spectrum features, including items on the mania and psychosis subscales of the Psychiatric Diagnos

79 as a previously unrecognized model of human mania and reveal an important role for CLOCK in the dopa

80 Bipolar mania and schizophrenia are recognized as separate disor

81 e lack of distinct endophenotypes of bipolar mania and schizophrenia has complicated the development

82 ls into question an accepted animal model of mania and should help to develop more accurate human and

83 hase of a unitary psychosis transitioning to mania and then dementia.

84 stability to mitigate recurrent episodes of mania and/or depression.

85 SM-5 criterion would alter the prevalence of mania and/or hypomania.

86 anxiety/depression, affective lability, and mania (and with a parent with older age at mood disorder

87 demarcating 3 groups: mania absent, episodic mania, and chronic mania (manic/hypomanic >1 year).

88 antisocial PD), thought disorder (psychosis, mania, and cluster A PDs), somatoform (somatoform disord

89 f symptoms, including psychosis, depression, mania, and cognitive deficits.

90 Co-occurring substance abuse, psychosis, mania, and cognitive impairment were exclusionary.

91 of schizophrenia, elevated in bipolar (hypo)mania, and contextually misallocated in the positive sym

92 for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by

93 stent with findings in bipolar I depression, mania, and euthymia, suggesting a physiologic trait mark

94 all of which investigated verapamil in acute mania, and finding no evidence that it is effective.

95 r current episode duration, preponderance of mania, and high rates of ultradian rapid cycling and com

96 rn is the risk for mood switch to hypomania, mania, and mixed states.

97 gy, low maternal warmth predicted relapse to mania, and more weeks ill with manic episodes was predic

98 red communication of temporal lobe epilepsy, mania, and Wernicke's aphasia-compared to the sparse spe

99 anxiety/depression, affective lability, and mania are important predictors of new-onset bipolar spec

100 ability, personality changes, psychosis, and mania are less common but equally distressing symptoms t

101 Psychiatric disorders such as addiction and mania are marked by persistent reward seeking despite hi

102 duration of manic diagnoses, using onset of mania as baseline date, was 79.2 +/- 66.7 consecutive we

103 valproate, the drugs presently used to treat mania associated with BD, rescued the hyperactive phenot

104 We included patients with acute mania associated with bipolar I disorder.

105 to determine the risk of treatment-emergent mania associated with methylphenidate, used in monothera

106 Mania at onset occurred at a later age on average than m

107 Mania at onset substantially increased the genetic linka

108 gely reflected relative pairs concordant for mania at onset, which occurred significantly more freque

109 d four unmedicated participants with bipolar mania (BM) (n = 30), bipolar depression (BD) (n = 30), b

110 (BPD), 30 with current bipolar hypomania or mania (BPM), 15 bipolar euthymic (BPE), and 30 healthy c

111 the hyperarousal symptoms characteristic of mania but who lack the well-demarcated periods of elevat

112 During follow-up, 87.8% recovered from mania, but 73.3% relapsed to mania.

113 is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level hav

114 iffer in time to recurrence of depression or mania, but patients in FFT-A spent fewer weeks in depres

115 ood and/or grandiosity), to avoid diagnosing mania by symptoms that overlapped with those for attenti

116 Treatment-emergent mania can have substantial negative impact on overall mo

117 predicted faster relapse after recovery from mania (chi(2) = 13.6, P =.0002), and psychosis predicted

118 exhibit impulsive responding, such as ADHD, mania, chronic substance abuse and schizophrenia.

119 th and onset of several disorders, including mania, confirm multiple case reports and results of smal

120 c or mixed phase) with at least one cardinal mania criterion (i.e., euphoria and/or grandiosity) to e

121 schizophrenia; and IL-1RA levels in bipolar mania decreased.

122 tioning on individual to compare the rate of mania (defined as hospitalization for mania or a new dis

123 assessed the incidence rates of depression, mania, delirium, panic disorder, and suicidal behaviors

124 Patients with bipolar mania demonstrated a unique exploratory pattern, charact

125 nge, 0.66-0.70) were dimensional measures of mania, depression, anxiety, and mood lability; psychosoc

126 re was time to recurrence of any mood event (mania, depression, or a mixed episode).

127 cluding suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusi

128 The components represented dimensions of mania, depression, positive symptoms, anxiety, negative

129 those in the other two groups, and new-onset mania developed in 2 patients in the tDCS group.

130 erience recurrent episodes of depression and mania, disrupting normal life and increasing the risk of

131 switches in mood polarity into hypomania or mania during acute and continuation trials of adjunctive

132 at least one of the two cardinal symptoms of mania (elated mood and/or grandiosity), to avoid diagnos

133 gnostically heterogeneous disorder, although mania emerges as a distinct phenotype characterized by e

134 th any mood episodes and 39.6% of weeks with mania episodes, during 8-year follow-up.

135 llele was significantly associated with the "mania" factor, in particular the subdimension "overactiv

136 Given the markedly increased hazard ratio of mania following methylphenidate initiation in bipolar pa

137 s that have been shown to best differentiate mania from ADHD (i.e., elation, grandiosity, flight of i

138 ere was a nearly 2-fold increase in rates of mania from ages 13-14 to 17-18 years.

139 The evidence for independence of mania from depression warrants additional scrutiny in th

140 of first-lifetime onset postpartum psychosis/mania from population-based register studies of psychiat

141 e compared with the mania absent and chronic mania groups (12-point and 8-point difference on GAF).

142 Diagnosis of child mania has been contentious.

143 difficult to represent in animals, models of mania have begun to decode its fundamental underlying ne

144 Due to increased impulsivity and risk for mania, however, depressed individuals with bipolar disor

145 kDelta19) have been identified as a model of mania; however, the mechanisms that underlie this phenot

146 r probability of recovery from an episode of mania (HR = 1.713; 95% CI, 1.373-2.137; P < .001), hypom

147 postpartum period, with a focus on managing mania, hypomania, and the psychotic components of the il

148 tly achieved recovery, time to recurrence of mania, hypomania, mixed state, or a depressive episode w

149 episode do not support the splitting between mania/hypomania and depression); family history, major d

150 polarity were observed for family history of mania/hypomania and multiple past mood episodes.

151 Duration of mania/hypomania showed 2 discontinuities demarcating 3 g

152 disorder rather than to stronger effects of mania/hypomania than depression.

153 MAIN OUTCOME MEASURES: Mania/hypomania with or without depression among those w

154 e psychosis to mood disturbance, duration of mania/hypomania, depression, and psychosis) and 10-year

155 e failure to evaluate the workplace costs of mania/hypomania.

156 irment of cognitive function, depression, or mania; impairment of reproductive and sexual function; a

157 ne was effective in the treatment of bipolar mania in adolescent patients.

158 icantly reduce the frequency and severity of mania in bipolar disorder, and cost increases are modest

159 lity is a diagnostic indicator for pediatric mania in bipolar disorder.

160 ontain genes influencing the age at onset of mania in bipolar disorder.

161 shold switches to full-duration hypomania or mania in both acute and long-term continuation treatment

162 re are limited data on the manifestations of mania in general community samples of adolescents.

163 This is highly consistent with mania in humans.

164 t to share face and predictive validity with mania in humans.

165 orrelates associated with treatment-emergent mania in patients receiving adjunctive antidepressant tr

166 nic risk score and the clinical dimension of mania in SCZ patients.

167 hm in patients with first-onset psychosis or mania in the postpartum period.

168 the YMRS items predicted treatment-emergent mania in this sample: increased motor activity, speech,

169 profile that is strikingly similar to human mania, including hyperactivity, decreased sleep, lowered

170 evel of valproate for best response in acute mania is above 94 microg/ml.

171 A first hospitalization for mania is associated with a period of recovery from comor

172 Mania is characterised by increased impulsivity and risk

173 pha activity in the ventral midbrain induced mania-like behavior in association with a central hyperd

174 al NAC phase signaling may contribute to the mania-like behavioral manifestations that result from di

175 r gross neural circuit function and generate mania-like behaviors in Clock-Delta19 mice.

176 5alphaR mediates a number of psychosis- and mania-like complications of SD through imbalances in cor

177 of either irritability or short episodes of mania-like symptoms in youth.

178 ther irritability or short-lived episodes of mania-like symptoms is still small.

179 en with short (less than 4 days) episodes of mania-like symptoms seem to progress to classical (Type

180 re chronic irritability or short episodes of mania-like symptoms, are common, impairing and a topic o

181 ith severe irritability or short episodes of mania-like symptoms.

182 1), and IL-1 receptor antagonist (p value in mania < .001 and euthymia = .021) were significantly ele

183 s: mania absent, episodic mania, and chronic mania (manic/hypomanic >1 year).

184 individual patterns of activity suggest that mania may be better characterized by differences in robu

185 of symptoms of depression or of hypomania or mania, measured by the Inventory of Depressive Symptomat

186 ategories based on symptomatic presentation--mania, melancholia and paranoia--all derived from the be

187 es are remission, subsyndromal and syndromal mania, mixed states or depression.

188 cation (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling).

189 face validity of the MSN strain as a complex mania model, adding sexual dimorphism, an altered diurna

190 ach involves analysis of naturally occurring mania models including an inbred strain our lab has rece

191 The principal mania models involve transgenic manipulations or treatme

192 of schizophrenia (N=65), bipolar disorder or mania (N=37), depressive psychosis (N=39), or other psyc

193 ld switches into full-duration hypomania and mania occurred in 11.4% and 7.9%, respectively, of the a

194 gnificantly higher risks of both first-onset mania (odds ratio (OR) for abuse: 2.23; 95% confidence i

195 nfluences the risk for psychotic features in mania of bipolar disorder patients.

196 in the placebo group) or hospitalization for mania (one in each group).

197 etime bipolar I or II disorder and 1.7%, for mania only.

198 ate of mania (defined as hospitalization for mania or a new dispensation of stabilizing medication) 0

199 ed events were psychosis, severe depression, mania or agitation, hallucinations, sleep disturbance, a

200 or mania symptom load at the study entry and mania or depression symptom severity at the 3-month foll

201 ifferentiate between disturbances related to mania or depression, which is necessary to understand th

202 with an increased risk of treatment-emergent mania or hypomania (0.926 [0.576-1.491], p=0.753), but 5

203 d significantly higher rates of subthreshold mania or hypomania (13.3% compared with 1.2%), manic, mi

204 and psychosis predicted more weeks ill with mania or hypomania (F(1,80) = 12.2, P =.0008).

205 (N=45), and those who had treatment-emergent mania or hypomania (N=46).

206 ts spent 56.9% +/- 28.8% of total weeks with mania or hypomania (unipolar or mixed), and 38.7% +/- 28

207 tment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) wer

208 There were 7 episodes of treatment-emergent mania or hypomania, 5 occurring in the combined treatmen

209 onse, clinical remission, treatment-emergent mania or hypomania, and tolerability (using dropout rate

210 ts with major depression predicted new-onset mania or hypomania.

211 sodes of major depression and in episodes of mania or hypomania.

212 iated with antidepressant treatment-emergent mania or hypomania.

213 with an increased risk of treatment-emergent mania or hypomania.

214 relative to healthy participants, those with mania or mixed mania would (1) exhibit incremental decre

215 rred within the first postpartum month, with mania or psychosis having an earlier onset than depressi

216 reatment: 2.10; CI=1.55, 2.83) and recurrent mania (OR for abuse: 1.55; CI=1.00, 2.40; OR for maltrea

217 a and MDEs (OR=.7, CI:.5-1.1), psychosis and mania (OR=1.0, CI:.4-2.7) or psychosis and MDEs (OR=1.0,

218 OR)=2.9, confidence interval (CI): 1.1-7.7), mania (OR=6.4, CI: 2.2-18.7) and MDEs (OR=2.0, CI: 1.5-2

219 ere strikingly similar to those of the human mania phenotype and may thus serve as a valid mouse mode

220 tion of the dopamine transporter matched the mania phenotype better than the effects of amphetamine,

221 The clinical significance of mania plus depression as demonstrated by a 1 in 5 suicid

222 , more rare but severe complications such as mania, psychotic symptoms, or delirium need individual p

223 The Young Mania Rating Scale (for manic symptoms) and the Clinical

224 on Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range, 0-44), Social and Occu

225 y of Depressive Symptomatology and the Young Mania Rating Scale (YMRS) at baseline and bimonthly inte

226 linician-Rated Version (IDS-C) and the Young Mania Rating Scale (YMRS) were administered at each visi

227 ton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to evaluate clinical

228 hange from baseline to endpoint in the Young Mania Rating Scale (YMRS), using the last-observation-ca

229 n Rating Scale for Anxiety (HRSA), and Young Mania Rating Scale (YMRS).

230 Efficacy was assessed with the Young Mania Rating Scale (YMRS).

231 ween baseline and change scores on the Young Mania Rating Scale (YMRS; range 0-60) up to 3 weeks for

232 r mixed episode of bipolar I disorder (Young Mania Rating Scale [YMRS] total score < or =12 and 21-it

233 Hamilton Depression Rating Scale, and Young Mania Rating Scale at baseline and week 14.

234 valuated by removing the 5 overlapping Young Mania Rating Scale items, a significant sex effect persi

235 ) or bipolar II disorder (22.5%) and a Young Mania Rating Scale score > or =14 entered open treatment

236 ania was defined at a given visit as a Young Mania Rating Scale score of 12 or higher and an Inventor

237 Improvement in mean Young Mania Rating Scale total score (adjusted for covariates)

238 ean baseline-to-endpoint change in the Young Mania Rating Scale total score was significantly greater

239 hange from baseline to endpoint in the Young Mania Rating Scale total score was the primary outcome m

240 an adverse effects questionnaire, the young mania rating scale, and cognitive assessment.

241 Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning

242 (Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning

243 ypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburgh Sleep Quality Ind

244 ent in manic symptoms, assessed by the Young Mania Rating Scale, was also observed, in addition to ot

245 essive symptomatology self-report, and young mania rating scale.

246 y of Depressive Symptomatology and the Young Mania Rating Scale.

247 -endpoint change in total score on the Young Mania Rating Scale.

248 ilton Depression Rating Scale, and the Young Mania Rating Scale.

249 rief Psychiatric Rating Scale, and the Young Mania Rating Scale.

250 significantly correlated with improvement in mania ratings.

251 SD) can trigger or exacerbate psychosis- and mania-related symptoms; the neurobiological basis of the

252 On mania-related tests, BAG1 TG mice recovered much faster

253 nitial severity range in patients with acute mania remains unclear.

254 ith depression and 50.9% of respondents with mania reporting severe role impairment.

255 =108) of the sample experienced hypomania or mania, resulting in revision of diagnoses for 12.2% to b

256 he Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)) at a mean of 14.2 months follow-

257 (the Clinician-Administered Rating Scale for Mania score) was also lower in the group treated with su

258 m was associated with a greater reduction in mania scores over 9 weeks.

259 teresting dispositional phenomena related to mania seen in MSN mice.

260 istory of childhood maltreatment had greater mania severity (six studies, 780 participants; odds rati

261 en groups in treatment-emergent hypomania or mania (six patients in the modafinil group and five in t

262 e relationship between antidepressant use or mania symptom load at the study entry and mania or depre

263 Differences in mania symptom profiles between investigative groups may

264 use was associated with significantly higher mania symptom severity at the 3-month follow-up.

265 2.09, P = .04) and the time with significant mania symptoms (19.2 vs 24.7 weeks; F(1) = 6.0, P = .01)

266 tion significantly reduced the mean level of mania symptoms (z = 2.09, P = .04) and the time with sig

267 NCAN preferentially affected mania symptoms in humans.

268 systematic care interventions effective for mania symptoms.

269 oor to fair for all cardinal and noncardinal mania symptoms.

270 identify defining characteristics of bipolar mania that are distinct from those of schizophrenia.

271 3beta) was studied in a novel mouse model of mania that has recently been validated with several clin

272 depressants did not induce more switching to mania (the event rate for antidepressants was 3.8% and f

273 rugs are effective in the acute treatment of mania; their efficacy in the treatment of depression is

274 In patients with acute mania, this inhibitory deficit has been correlated with

275 cts of adolescents in their first episode of mania to address whether abnormalities are present in ea

276 The increased risk of treatment-emergent mania was confined to patients on antidepressant monothe

277 Mania was defined by DSM-IV criteria, with at least one

278 oms at baseline with subsequent hypomania or mania was determined in survival analyses using Cox prop

279 atients taking mood stabilizers, the risk of mania was lower after starting methylphenidate (hazard r

280 mood stabilizer, no acute change in risk of mania was observed during the 3 months after the start o

281 ed studies of divalproex treatment for acute mania was performed to test a hypothesized linear relati

282 ATPase alpha3 Myshkin (Myk/+) mouse model of mania was performed.

283 However, no risk of mania was seen in patients receiving an antidepressant w

284 The age at onset of mania was significantly heritable in these families.

285 first episodes, second and third episodes of mania were characterized by psychosis, daily (ultradian)

286 were observed when only hospitalizations for mania were counted.

287 their index major depressive episode and/or mania were divided into residual vs asymptomatic recover

288 eficits in patients with bipolar disorder or mania were less pervasive but evident in performance sco

289 with depression alone, whereas correlates of mania were similar among those with mania with or withou

290 of full-duration hypomania [> or =7 days] or mania) were blindly assessed by using clinician-rated da

291 on of mood symptoms have stronger effects on mania, whereas treatments that emphasize cognitive and i

292 haviors of children at high and low risk for mania while they anticipate and respond to reward and lo

293 isk of delirium/confusion/disorientation and mania, while younger patients were at higher risk of sui

294 increased dopaminergic neurotransmission and mania, whilst increased striatal dopamine transporter (D

295 nal study of 86 subjects with intake episode mania who were all assessed at 6, 12, 18, 24, 36, and 48

296 Twelve-month rates of mania with and without depression were 2.2% and 1.3%, re

297 ether with high rates of clinical overlap of mania with anxiety and substance use disorders provide a

298 Mania with depression was associated with a greater numb

299 lates of mania were similar among those with mania with or without depression.

300 lthy participants, those with mania or mixed mania would (1) exhibit incremental decrements in sustai